Trials / Completed
CompletedNCT05985590
A Study to Investigate the Effects of BMS-986278 on Drospirenone and Ethinyl Estradiol Drug Levels in Healthy Female Participants
A Phase 1, Open-label, Fixed-sequence Study to Investigate the Effects of Multiple Doses of BMS-986278 on the Pharmacokinetics of Combined Oral Contraceptives (Drospirenone/Ethinyl Estradiol) in Healthy Female Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 37 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- Female
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The purpose of the study is to assess the effects of BMS-986278 on Drospirenone (DRSP) and Ethinyl Estradiol (EE) when administered as a combined oral contraceptive in healthy female participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-986278 | Specified dose on specified days |
| DRUG | Drospirenone/Ethinyl Estradiol | Specified dose on specified days |
Timeline
- Start date
- 2023-08-18
- Primary completion
- 2023-12-11
- Completion
- 2023-12-11
- First posted
- 2023-08-14
- Last updated
- 2024-01-24
Locations
1 site across 1 country: Canada
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05985590. Inclusion in this directory is not an endorsement.